Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma

OBJECTIVE AND METHODS: In this phase 1b study, patients with stage 4 or unresectable stage 3 melanoma were treated with escalating doses of lenvatinib (once daily) and temozolomide (TMZ) (days 1–5) in 28-day cycles, to determine the maximum tolerated dose (MTD) of the combination. Dose Level (DL)1:...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, David S., Kurzrock, Razelle, Falchook, Gerald S., Andresen, Corina, Kwak, Jennifer, Ren, Min, Xu, Lucy, George, Goldy C., Kim, Kevin B., Nguyen, Ly M., O'Brien, James P., Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767496/
https://www.ncbi.nlm.nih.gov/pubmed/26503473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767496/
https://www.ncbi.nlm.nih.gov/pubmed/26503473

Ejemplares similares